CSI Intelligent Finance Yifan Pharmaceutical (002019) disclosed its third quarter report for 2022 on October 29. In the first three quarters of 2022, the company achieved total operating income of 2.729 billion yuan, a year-on-year decrease of 19.68%; net profit attributable to shareholders was 203 million yuan, a year-on-year decrease of 30.10%; net profit excluding non-operating items was 130 million yuan, a year-on-year decrease of 47.89%; net cash flow generated by operating activities was 273 million yuan, a year-on-year decrease of 16.68%; during the reporting period, Yifan Pharmaceutical basic earnings per share was 0.16 yuan, and the weighted average return on equity was 2.34%.
During the reporting period, the company's total non-recurring gains and losses of were 72.9726 million yuan, of which 80.1466 million yuan of government subsidies included in the current profit and loss, and the profit and loss of non-current assets (including the reversal part of 's asset impairment provisions) was -2.4584 million yuan.
According to the third quarter report, the company achieved total operating income of 960 million yuan in the third quarter, a year-on-year decrease of 5.94% and a month-on-month increase of 11.13%; net profit attributable to shareholders was 42.696 million yuan, a year-on-year decrease of 45.00% and a month-on-month increase of 8.66%; net profit excluding non-network was 24.9254 million yuan, a year-on-year decrease of 62.08% and a month-on-month decrease of 12.65%.
In the first three quarters of 2022, the company's gross profit margin was 51.21%, an increase of 10.69 percentage points year-on-year; the net profit margin was 5.51%, a decrease of 1.62 percentage points from the same period last year. Judging from the single-quarter indicators, the company's gross profit margin in the third quarter of 2022 was 51.24%, up 9.54 percentage points year-on-year and 1.75 percentage points month-on-month; the net profit margin was 2.08%, down 3.85 percentage points from the same period last year and 0.91 percentage points from the previous quarter.
In the third quarter of 2022, the company's return on equity was 0.49%, a year-on-year decrease of 0.41 percentage points and a month-on-month increase of 0.04 percentage points.
In the first three quarters of 2022, the company's net cash flow in operating activities was 273 million yuan, a year-on-year decrease of 16.68%; the net cash flow of financing activities was 355 million yuan, a year-on-year increase of 171 million yuan; the net cash flow of investment activities was -400 million yuan, a year-on-year decrease of -660 million yuan.
In the first three quarters of 2022, the company's operating income cash ratio was 116.13%, and the net cash ratio was 134.42%.
In the first three quarters of 2022, the company's period expenses were 1.229 billion yuan, an increase of 150 million yuan from the same period last year; the period expense ratio was 45.02%, an increase of 13.27 percentage points from the same period last year. Among them, sales expenses increased by 24.04% year-on-year, administrative expenses increased by 7.16% year-on-year, R&D expenses decreased by 1.72% year-on-year, and financial expenses decreased by 38.88% year-on-year.
According to the announcement, changes in financial expenses are mainly due to the rise in the US dollar exchange rate, resulting in an increase in exchange income and loan interest expenses.
In terms of major changes in assets, as of the end of the third quarter of 2022, the company's inventory increased by 26.34% from the end of the previous year, accounting for 1.15 percentage points of the company's total assets; intangible assets increased by 17.40% from the end of the previous year, accounting for 0.68 percentage points of the company's total assets; cash and cash funds decreased by 1.34% from the end of the previous year, accounting for 0.60 percentage points of the company's total assets; fixed assets decreased by 0.70% from the end of the previous year, accounting for 0.51 percentage points of the company's total assets. In terms of major changes in liabilities of
, as of the end of the third quarter of 2022, the company's long-term loans increased by 40.94% from the end of the previous year, accounting for 2.11 percentage points of the company's total assets; short-term loans decreased by 2.65% from the end of the previous year, accounting for 0.55 percentage points of the company's total assets; accounts payable decreased by 10.68% from the end of the previous year, accounting for 0.41 percentage points of the company's total assets; non-current liabilities due within one year, accounting for increased by 0.81% from the end of the previous year, accounting for 0.12 percentage points of the company's total assets. In terms of debt repayment ability, the company's debt-to-asset ratio at the end of the third quarter of 2022 was 28.14%, an increase of 0.27 percentage points from the end of the previous year; the interest-bearing debt-to-asset ratio of was 19.26%, an increase of 1.43 percentage points from the end of the previous year.
The third quarter report shows that among the top ten circulating shareholders of the company at the end of the third quarter of 2022, the new shareholders were Anhui Zhongan Health Investment Management Co., Ltd.-Anhui Zhongan Health Elderly Care Service Industry Investment Partnership (Limited Partnership), replacing the Cathay Big Health Stock Securities Investment Fund at the end of the second quarter. In terms of specific shareholding ratios, the holdings of Cheng Xianfeng, Hong Kong Central Clearing Co., Ltd., Huang Xiaomin, Zheng Zhen, Fang Ming, Yingshui Qianlong No. 13 Private Equity Securities Investment Fund , Yingshui Xunyang No. 4 Private Equity Securities Investment Fund, Yingshui Harmony No. 7 Private Equity Securities Investment Fund, and Shenzhen Guodiao Merger and Acquisition Equity Investment Fund Partnership (Limited Partnership) have increased.
| Share name | Stakeholder shares (ten thousand shares) | Sales proportion (%) | Total share capital (%) | Change ratio (%) |
|---|---|---|---|---|
| Cheng Pioneer | 12413.16 | 10.12472 | 0.07 | |
| Hong Kong Central Settlement Co., Ltd. | 1907.74 | 1.556036 | 0.12 | 1. 0|
| Huang Xiaomin | 950 | 0.774862 | 0.01 | |
| 0.02 | ||||
| Zheng Zhen | 934.66 | 0.762352 | 0.09 | |
| Fang Ming | 865.52 | 0.705956 | 0.02 | |
| Yingshui Kuanglong No. 13 Private equity securities investment fund | 8 23 | 0.671275 | 0.00 | |
| Yingshui Xunyang No. 4 Private Equity Securities Investment Fund | 822 | 0.67046 | 0.00 | |
| Yingshui Harmony No. 7 Private Equity Securities Investment Fund | 822 | 0.67046 | 0.00 | |
| Shenzhen Guodiao Investment Merchants and Acquisition Equity Investment Fund Partnership (Limited Partnership) | 775 .99 | 0.632932 | 0.00 | |
| Anhui Zhongan Health Investment Management Co., Ltd.-Anhui Zhongan Health Elderly Care Service Industry Investment Partnership (Limited Partnership) | 730 | 0.59542 | New |
In terms of chip concentration, as of the end of the third quarter of 2022, the total number of shareholders of the company was 52,000, an increase of 3,555 from the end of the second quarter, an increase of 7.34%; the average shareholding market value dropped from 356,100 yuan at the end of the second quarter to 246,600 yuan, a decrease of 30.75%.
